Gene · 6554
Papers3,134
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
481 to 500 of 3,134
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A focused review of statistical practices for relating radiation dose-volume exposure and toxicity. | Radiat Oncol | 2023 | 36964622 | PubTator, text mining | PubMed |
| Structural conservation of HBV-like capsid proteins over hundreds of millions of years despite the shift from non-enveloped to enveloped life-style. | Nat Commun | 2023 | 36949039 | PubTator, text mining | PubMed |
| Drug-disease interaction: Clinical consequences of inflammation on drugs action and disposition. | J Pharm Pharm Sci | 2023 | 36942294 | PubTator, text mining | PubMed |
| Small molecule metabolites: discovery of biomarkers and therapeutic targets. | Signal Transduct Target Ther | 2023 | 36941259 | PubTator, text mining | PubMed |
| Abnormally primed CD8 T cells: The Achilles' heel of CHB. | Front Immunol | 2023 | 36936922 | PubTator, text mining | PubMed |
| Amentoflavone inhibits hepatitis B virus infection via the suppression of preS1 binding to host cells. | Microbiol Immunol | 2023 | 36929353 | PubTator, text mining | PubMed |
| Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease. | Nat Commun | 2023 | 36927865 | PubTator, text mining | PubMed |
| Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA. | J Viral Hepat | 2023 | 36924318 | PubTator, text mining | PubMed |
| Serum miR-4488 as a potential biomarker of lean nonalcoholic fatty liver disease. | Ann Transl Med | 2023 | 36923095 | PubTator, text mining | PubMed |
| C2729T mutation associated with HBV mother-to-child transmission reduces HBV production via suppressing LHBs expression. | Virulence | 2023 | 36919573 | PubTator, text mining | PubMed |
| Strain-specific responsiveness of hepatitis D virus to interferon-alpha treatment. | JHEP Rep | 2023 | 36908749 | PubTator, text mining | PubMed |
| Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist. | Clin Pharmacokinet | 2023 | 36906733 | PubTator, text mining | PubMed |
| The Multiple Facets and Disorders of B Cell Functions in Hepatitis B Virus Infection. | J Clin Med | 2023 | 36902786 | PubTator, text mining | PubMed |
| Relevance of HBx for Hepatitis B Virus-Associated Pathogenesis. | Int J Mol Sci | 2023 | 36902395 | PubTator, text mining | PubMed |
| A Dual Coverage Monitoring of the Bile Acids Profile in the Liver-Gut Axis throughout the Whole Inflammation-Cancer Transformation Progressive: Reveal Hepatocellular Carcinoma Pathogenesis. | Int J Mol Sci | 2023 | 36901689 | PubTator, text mining | PubMed |
| Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions. | Asian J Pharm Sci | 2023 | 36896445 | PubTator, text mining | PubMed |
| Odevixibat: A Review of a Bioactive Compound for the Treatment of Pruritus Approved by the FDA. | Curr Drug Res Rev | 2023 | 36892028 | PubTator, text mining | PubMed |
| Assessment of the drug-drug interaction potential for therapeutic proteins with pro-inflammatory activities. | Clin Transl Sci | 2023 | 36890677 | PubTator, text mining | PubMed |
| A decade of liver organoids: Advances in disease modeling. | Clin Mol Hepatol | 2023 | 36880210 | PubTator, text mining | PubMed |
| Cholestasis: exploring the triangular relationship of gut microbiota-bile acid-cholestasis and the potential probiotic strategies. | Gut Microbes | 2023 | 36864554 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6554/papers?page=25